Health concerns consultations

Health Canada recognizes that one of the key challenges in governance today is meaningful public involvement in policy and programme development, service delivery, and legislative and regulatory initiatives. Canadians are better educated and informed than ever before, and they expect to have a say in public policy decision-making. On this page, you will find an overview of current public consultations in which you can take part, and you can find out about past consultations as well.

What Information is Available

This section provides information on consultation opportunities going on in the area of Health Concerns.

Find more information on the departmental consultation activities.

2022

• Consultation: Amendments to the Cannabis Regulations and other regulations concerning cannabis research and testing, and cannabis beverages

2021

• Consulting about flavours in inhaled cannabis extracts: Amending the Cannabis Regulations
• Consultation on guidance on personal production of cannabis for medical purposes

2020

• Consultation to inform proposed new regulations for supervised consumption sites and services

2019

• Consultation - Reducing Youth Access and Appeal of Vaping Products: Potential Regulatory Measures
• Consultation - Potential measures to reduce the impact of vaping products advertising on youth and non-users of tobacco products
• Consultation: Destruction of controlled substances and travel with controlled substances for medical use
• Consultation on Proposals to Amend the Tobacco Reporting Regulations
• Consultation on potential market for cannabis health products that would not require practitioner oversight 

2018

• Consultation on New Health Labelling for Tobacco Products
• Consultation on palliative care
• Proposed Approach to the Regulation of Cannabis
• Proposed Approach to Cost Recovery for the Regulation of Cannabis

2017

• Consultation on proposals for the regulation of vaping products
• Consultation: Access to substances temporarily controlled under the CDSA
• Consultation on the regulatory amendment regarding ¹²³I-ioflupane
• Consultation on the future of tobacco control in Canada
• Consultation - Proposed Order Amending Schedule III to the Controlled Drugs and Substances Act and Regulations Amending Part G to the Food and Drug Regulations with Respect to Aminorex
• Consultation - Proposed Order to amend the Schedule to the Tobacco Act (Menthol)
• Consultation: Regulations for reference standards under the CDSA
• Consultation: Non-prescription availability of low-dose codeine products

2016

• Consultation - Proposed Order Amending Schedule VI to the Controlled Drugs and Substances Act and Regulations Amending the Schedule to the Precursor Control Regulations with Respect to Six Chemicals Used in the Production of Fentanyl
• Consultation on New Regulations for Antimicrobial Resistance Related to Veterinary Drugs
• Consultation on Potential Measures to Regulate Tobacco Packages and Products
• Notice to Interested Parties - Proposed Order to amend the Schedule to the Tobacco Act (Menthol)
• Consultation Proposed Regulations Amending Certain Regulations Relating to Access to Diacetylmorphine for Emergency Treatment
• Consultation - Proposed order amending Schedule III to the Controlled Drugs and Substances Act and Regulations amending Part J of the Food and Drug Regulations with respect to methylphenidate
• Consultation - Proposal regarding the scheduling of W-18 under the Controlled Drugs and Substances Act and its Regulations

2015

• Consultation - Proposal regarding the scheduling of AH-7921 and MT-45 under the Controlled Drugs and Substances Act and its Regulations
• Consultation - Proposal regarding the scheduling of 2C-phenethylamines under the Controlled Drugs and Substances Act and its regulations
• Notice of Pre-Consultation - Draft Tamper-Resistant Properties of Drugs Regulation
• Consultation - Regulatory amendments regarding the salts of apomorphine, cyprenorphine, narcotine, papaverine, carbamethidine, oxpheneridine, ethoheptazine, metethoheptazine, metheptazine, dextromethorphan, dextrorphan, levallorphan, levargorphan and cyclazocine
• Consultation - Proposed Regulations Amending Regulations under the Controlled Drugs and Substances Act with Respect to the Issuance of Licences and Permits
• Consultation - Regulatory Amendments Regarding Barbituric Acid, Naloxegol, Methylnaltrexone, Catha edulis Forsk, Cathine and Cathinone and the Salts of Nalmefene, Naloxone and Naltrexone
• Order Amending the Schedule to the Tobacco Act

2014

• Notice of Proposed Order to amend the Schedule to the Tobacco Act
• Notice of Intent to Interested Parties: Tamper Resistance under the Controlled Drugs and Substances Act

2013

• Consultation on Health Canada's Review of the Industrial Hemp Framework

2004

• Proposal for New Health-Related Information on Tobacco Product Labels - A Consultation Paper